Biotech M&A Booms, But Have Buyouts Reached a Tipping Point?
Pathfinders in Biopharma - Un pódcast de RBC Capital Markets
Categorías:
In the latest episode of Pathfinders, Senior Biotechnology Analyst Gregory Renza discusses what’s driving the latest spate of biotech M&A activity — the new players and partnership dynamics that are creating what he calls “a landscape of competition” in the broader market.
